T. Rowe Price Associates’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$311K Buy
82,328
+7,122
+9% +$26.9K ﹤0.01% 2511
2025
Q1
$341K Buy
75,206
+12,763
+20% +$57.9K ﹤0.01% 2409
2024
Q4
$442K Buy
62,443
+4,798
+8% +$34K ﹤0.01% 2326
2024
Q3
$470K Buy
57,645
+557
+1% +$4.54K ﹤0.01% 2270
2024
Q2
$365K Buy
57,088
+7,342
+15% +$46.9K ﹤0.01% 2320
2024
Q1
$375K Buy
49,746
+2,831
+6% +$21.3K ﹤0.01% 2326
2023
Q4
$435K Buy
46,915
+4,941
+12% +$45.8K ﹤0.01% 2233
2023
Q3
$425K Buy
41,974
+1,541
+4% +$15.6K ﹤0.01% 2189
2023
Q2
$506K Buy
40,433
+676
+2% +$8.46K ﹤0.01% 2119
2023
Q1
$464K Buy
39,757
+970
+3% +$11.3K ﹤0.01% 2146
2022
Q4
$412K Buy
38,787
+3,613
+10% +$38.4K ﹤0.01% 2223
2022
Q3
$342K Buy
35,174
+8,887
+34% +$86.4K ﹤0.01% 2315
2022
Q2
$381K Buy
26,287
+5,804
+28% +$84.1K ﹤0.01% 2329
2022
Q1
$535K Buy
20,483
+5,142
+34% +$134K ﹤0.01% 2298
2021
Q4
$608K Sell
15,341
-664
-4% -$26.3K ﹤0.01% 2298
2021
Q3
$800K Buy
16,005
+491
+3% +$24.5K ﹤0.01% 2147
2021
Q2
$861K Buy
15,514
+1,431
+10% +$79.4K ﹤0.01% 2128
2021
Q1
$659K Buy
14,083
+13
+0.1% +$608 ﹤0.01% 2230
2020
Q4
$612K Sell
14,070
-170,213
-92% -$7.4M ﹤0.01% 2162
2020
Q3
$6.75M Sell
184,283
-156,607
-46% -$5.73M ﹤0.01% 1366
2020
Q2
$9.94M Sell
340,890
-134,384
-28% -$3.92M ﹤0.01% 1297
2020
Q1
$12.4M Buy
475,274
+194,037
+69% +$5.07M ﹤0.01% 1190
2019
Q4
$9.76M Sell
281,237
-19,499
-6% -$677K ﹤0.01% 1316
2019
Q3
$9.52M Buy
+300,736
New +$9.52M ﹤0.01% 1300